Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBA-1331
- Development stage
- Preclinical
- Lead developer
- Kling Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
KBA-1331 is a fully human antibody drug candidate developed by Kling Biotherapeutics. It was identified from the B cell repertoire of multiple acute myeloid leukemia (AML) survivors and is designed to bind an ectopic antigen on AML cells. The antibody targets SNRNP200 (small nuclear ribonucleoprotein U5 subunit 200), acting as an inhibitor of this protein. Its mechanism aims to exploit unique vulnerabilities in AML cells for targeted therapy, with preclinical development focused on neoplasms, particularly hemic and lymphatic diseases such as AML[1][4][9].
- Other names
- anti-snRNP200 antibodyanti-snRNP-200 antibodyanti-snRNP 200 antibodyanti-U5snRNP200 antibodyanti-U-5snRNP200 antibodyanti-U 5snRNP200 antibodyanti-snRNP200 monoclonal antibodyanti-snRNP-200 monoclonal antibodyanti-snRNP 200 monoclonal antibody
02
Targets
SNRNP200 (Small nuclear ribonucleoprotein U5 subunit 200)
Beyond the preview
Go deeper on KBA-1331.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBA-1331.